Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MedImmune Gets Back FluMist: Physicians Will Be Focus Post-Wyeth

  • News

Executive Summary

MedImmune is getting "back to basics" on FluMist promotional efforts with a focus on physician education now that the company has regained sole rights to the intranasal flu vaccine from Wyeth

You may also be interested in...



ID Biomedical Seeking FluINsure Development Partner For U.S. Market

ID Biomedical is seeking a development partner for securing U.S. approval of its inactived intranasal flu vaccine FluINsure, President Todd Patrick said

ID Biomedical Seeking FluINsure Development Partner For U.S. Market

ID Biomedical is seeking a development partner for securing U.S. approval of its inactived intranasal flu vaccine FluINsure, President Todd Patrick said

Vaccine Stockpiling Will Not Encourage Development, Wyeth Exec Says

Vaccine manufacturers look for market growth potential when selecting projects, Wyeth Exec VP George Siber, MD, said

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS043876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By